|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Vargatef>> Market Analysis Reports |
Market Analysis Reports of Vargatef |
|
CAS 656247-17-5 Intedanib Chemical Report & Database ... definitions: Name: Intedanib: Intedanib; Vargatef; BIBF 1120 Synonyms: Vargatef; BIBF 1120 Chemical ... Non-Small Cell Lung Cancer: KOL Insight ... ’s Iressa, Boehringer Ingelheim’s Gilotrif and Vargatef, Pfizer’s Xalkori, Novartis’ Zykadia, Roche ... NSCLC [2017] ... (alectinib; Roche) Alunbrig (brigatinib; Takeda) Vargatef (nintedanib; Boehringer Ingelheim) Portrazza (necitumumab ... Ovarian Cancer: KOL Insight ... tumour cell vaccine; Gradalis) Nintedanib (Vargatef; Boehringer Ingelheim) Ofranergene obadenovec (VB-111 ... Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. The global increase in the prevalence of cancer and the increasing recognition of the therapeutic and commercial opportunities offered by new ... NSCLC: KOL Insight ... -negative NSCLC Avastin (bevacizumab; Roche) Vargatef (nintedanib; Boehringer Ingelheim) Cyramza (ramucirumab ... Colorectal Cancer KOL Insight 2016 KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). Some say novel therapies are the key. Others argue ... Ovarian Cancer [2017] How will new combination regimens impact the ovarian cancer treatment landscape? Competition is intensifying in the PARP inhibitor space due to the recent approval of Clovis’ Rubraca and Tesaro/Merck & Co.’s Zejula. How will AstraZeneca’s Lynparza fare in ... Therapies for Resistant and Recurrent Metastatic Cancer The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022. The lung cancer market is expected to grow from $15.7 billion in 2017 to $22.6 billion ... Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY According to the recently published ... |